BioXcel Therapeutics (BTAI) Scheduled to Post Earnings on Thursday

BioXcel Therapeutics (NASDAQ:BTAI) will announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Tuesday, March 12th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.22. BioXcel Therapeutics had a negative net margin of 12,974.86% and a negative return on equity of 890.63%. The business had revenue of $0.38 million for the quarter, compared to the consensus estimate of $1.17 million. On average, analysts expect BioXcel Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioXcel Therapeutics Price Performance

NASDAQ BTAI opened at $2.35 on Wednesday. The company’s 50 day simple moving average is $2.78 and its 200 day simple moving average is $3.16. BioXcel Therapeutics has a 12 month low of $1.91 and a 12 month high of $29.56. The company has a market capitalization of $87.02 million, a P/E ratio of -0.38 and a beta of 0.43.

Analyst Ratings Changes

A number of analysts recently commented on BTAI shares. UBS Group reiterated a “neutral” rating and issued a $4.00 target price (down from $9.00) on shares of BioXcel Therapeutics in a report on Wednesday, February 21st. Bank of America cut their price target on shares of BioXcel Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Canaccord Genuity Group cut their price target on shares of BioXcel Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, March 14th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of BioXcel Therapeutics in a report on Tuesday, April 23rd. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $16.71.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.